Source:http://linkedlifedata.com/resource/pubmed/id/15375578
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2004-9-17
|
pubmed:abstractText |
Vascular targeting is a novel strategy that directs endothelial toxins at tumor vessels expressing specific markers and kills tumor cells by vascular occlusion. Integrin-binding RGD motif has been reported to have a homing property to experimental tumor vasculature. In the present study, we evaluated the effect of vascular targeting by doxorubicin-RGD-4C conjugate in an orthotopic murine hepatoma model. MTT assay showed that dox-RGD-4C conjugates had lower cytotoxicity against MH134 mouse hepatoma cells than free dox. When given intravenously to mice with implanted orthotopic hepatoma, however, the dox-RGD-4C suppressed the growth of hepatoma more effectively than free dox (mean tumor volumes 24 mm(3) vs. 67 mm(3), respectively; p=0.047). Histologic analysis of the hepatoma tissue revealed prominent tumor cell death in the dox-RGD-4C treated group and complete tumor cell necrosis in 40% of cases. Immunochemical staining showed expression of integrin alphav mainly around the tumor nodule. These results show that dox-RGD-4C conjugate has a better antitumor effect in an orthotopic mouse hepatoma model by tumor targeting. Integrin alphav of hepatoma feeding vessels is suggested to be targeted by the dox-RGD-4C conjugate.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alphaV,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alphaVbeta3,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/doxorubucin...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1107-3756
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
529-35
|
pubmed:meshHeading |
pubmed-meshheading:15375578-Animals,
pubmed-meshheading:15375578-Antineoplastic Agents,
pubmed-meshheading:15375578-Carcinoma, Hepatocellular,
pubmed-meshheading:15375578-Cell Line, Tumor,
pubmed-meshheading:15375578-Chromatography, High Pressure Liquid,
pubmed-meshheading:15375578-Disease Models, Animal,
pubmed-meshheading:15375578-Doxorubicin,
pubmed-meshheading:15375578-Immunohistochemistry,
pubmed-meshheading:15375578-Integrin alphaV,
pubmed-meshheading:15375578-Integrin alphaVbeta3,
pubmed-meshheading:15375578-Male,
pubmed-meshheading:15375578-Mice,
pubmed-meshheading:15375578-Molecular Structure,
pubmed-meshheading:15375578-Neoplasm Transplantation,
pubmed-meshheading:15375578-Oligopeptides
|
pubmed:year |
2004
|
pubmed:articleTitle |
Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
|
pubmed:affiliation |
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 28 Yungun-dong, Chongno-gu, Seoul 100-744, South Korea.
|
pubmed:publicationType |
Journal Article
|